COBALT represented RP PHARMA in a complex Phase II merger clearance case in the healthcare sector

COBALT successfully represented RP PHARMA in a complex concentration that was allowed by the Competition Council of the Republic of Lithuania in case the obligations are fulfilled properly.

The Competition Council has acknowledged that the investment fund INVL Baltic Sea Growth Fund and the companies Litgaja and RP PHARMA have duly fulfilled the conditions and obligations imposed on them, therefore can acquire the joint control of companies InMedica and, indirectly, of MediCA klinikos, Kardiolitos, Bendrosios medicinos praktikos and Svalbono klinikos.

The Competition Council drew these conclusions on the basis of both the final report provided by the team of the Trustee, which assisted the Authority in monitoring the implementation of the conditions set out in the commitments, and the information gathered by the Competition Council’s own experts.

COBALT consulted the client before and during the whole Phase II merger clearance process, consulted on the possible commitments enabling to clear the acquisition and assisted the client during the process of accepting and fulfilling the divesture commitments. The project team consisted of COBALT partner Rasa Zaščiurinskaitė and Senior Associate Laura Ryzgelytė.